Abstract
l-DOPA therapy of Parkinsonism by mouth, today universally accepted, may induce undesirable effects which can sometimes be of a certain severity. Gastrointestinal complaints and hypotension may be dependent from the dose of the drug, which can exert an irritating action on the gastric mucous, or may be due to a higher level of circulating catecholamines. Involuntary movements depend from a stimulating action on certain mesencephalic-diencephalic pathways. Pharmacologists have therefore tried to obviate these inconvenients, through the introduction of the peripheral DOPA-decarboxylase inhibitors; the administration of these drugs led to the following results in the animal: reduction of dosage consequent to a more sustained blood level of l-DOPA, reduction of side effects, possible decrease of involuntary movements. The data are obtained comparing two groups of patients: the first group (60 cases) treated with l-DOPA per os, the second group (24 cases) treated with an association of l-DOPA + decarboxylase inhibitor (Ro 8-0576, each capsule containing l-DOPA, 200 mg and Ro 4-4602, 50 mg). According to the results achieved, it can be stated that: 1. Ro 8-0576 gives a lower incidence of side effects; 2. the latency to achieve the therapeutic effect is shorter with Ro 8-0576; 3. this drug allows a greater benefit on tremor (55% with Ro 8-0576, 48% with l-DOPA only). Furthermore, the chief parkinsoniam symptoms (tremor, rigidity, akinesia) are better influenced.
| Original language | English |
|---|---|
| Pages (from-to) | 347-355 |
| Number of pages | 9 |
| Journal | Zeitschrift für Neurologie |
| Volume | 202 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Dec 1972 |
Fingerprint
Keywords
- Decarboxylase Inhibitor
- l-DOPA
- Parkinson's Disease
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Medicine(all)
Cite this
Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor. / Fazio, C.; Agnoli, A.; Casacchia, M.; Reitano, M.; Ruggieri, S.; Barba, C.; Volante, F.
In: Zeitschrift für Neurologie, Vol. 202, No. 4, 12.1972, p. 347-355.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor
AU - Fazio, C.
AU - Agnoli, A.
AU - Casacchia, M.
AU - Reitano, M.
AU - Ruggieri, S.
AU - Barba, C.
AU - Volante, F.
PY - 1972/12
Y1 - 1972/12
N2 - l-DOPA therapy of Parkinsonism by mouth, today universally accepted, may induce undesirable effects which can sometimes be of a certain severity. Gastrointestinal complaints and hypotension may be dependent from the dose of the drug, which can exert an irritating action on the gastric mucous, or may be due to a higher level of circulating catecholamines. Involuntary movements depend from a stimulating action on certain mesencephalic-diencephalic pathways. Pharmacologists have therefore tried to obviate these inconvenients, through the introduction of the peripheral DOPA-decarboxylase inhibitors; the administration of these drugs led to the following results in the animal: reduction of dosage consequent to a more sustained blood level of l-DOPA, reduction of side effects, possible decrease of involuntary movements. The data are obtained comparing two groups of patients: the first group (60 cases) treated with l-DOPA per os, the second group (24 cases) treated with an association of l-DOPA + decarboxylase inhibitor (Ro 8-0576, each capsule containing l-DOPA, 200 mg and Ro 4-4602, 50 mg). According to the results achieved, it can be stated that: 1. Ro 8-0576 gives a lower incidence of side effects; 2. the latency to achieve the therapeutic effect is shorter with Ro 8-0576; 3. this drug allows a greater benefit on tremor (55% with Ro 8-0576, 48% with l-DOPA only). Furthermore, the chief parkinsoniam symptoms (tremor, rigidity, akinesia) are better influenced.
AB - l-DOPA therapy of Parkinsonism by mouth, today universally accepted, may induce undesirable effects which can sometimes be of a certain severity. Gastrointestinal complaints and hypotension may be dependent from the dose of the drug, which can exert an irritating action on the gastric mucous, or may be due to a higher level of circulating catecholamines. Involuntary movements depend from a stimulating action on certain mesencephalic-diencephalic pathways. Pharmacologists have therefore tried to obviate these inconvenients, through the introduction of the peripheral DOPA-decarboxylase inhibitors; the administration of these drugs led to the following results in the animal: reduction of dosage consequent to a more sustained blood level of l-DOPA, reduction of side effects, possible decrease of involuntary movements. The data are obtained comparing two groups of patients: the first group (60 cases) treated with l-DOPA per os, the second group (24 cases) treated with an association of l-DOPA + decarboxylase inhibitor (Ro 8-0576, each capsule containing l-DOPA, 200 mg and Ro 4-4602, 50 mg). According to the results achieved, it can be stated that: 1. Ro 8-0576 gives a lower incidence of side effects; 2. the latency to achieve the therapeutic effect is shorter with Ro 8-0576; 3. this drug allows a greater benefit on tremor (55% with Ro 8-0576, 48% with l-DOPA only). Furthermore, the chief parkinsoniam symptoms (tremor, rigidity, akinesia) are better influenced.
KW - Decarboxylase Inhibitor
KW - l-DOPA
KW - Parkinson's Disease
UR - http://www.scopus.com/inward/record.url?scp=0015443668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015443668&partnerID=8YFLogxK
U2 - 10.1007/BF00316182
DO - 10.1007/BF00316182
M3 - Article
C2 - 4117654
AN - SCOPUS:0015443668
VL - 202
SP - 347
EP - 355
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
IS - 4
ER -